Daniel A Pollyea, MD, MS
Chen S et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, Phase 2 trial. ASH 2021;Abstract 35.
Daver N et al. Phase I/II study of azacitidine (aza) with venetoclax (ven) and magrolimab (magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH 2021;Abstract 371.
DiNardo CD et al. A Phase 3 study of enasidenib (ena) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (mIDH2) relapsed/refractory acute myeloid leukemia (R/R AML). EHA 2021;Abstract EP457.
DiNardo CD et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 2021;22(11):1597-608. Abstract
Lachowiez C et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. ASH 2021;Abstract 701.
Lachowiez CA et al. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. ASCO 2021;Abstract 7012.
Montesinos P et al. AGILE: A global, randomized, double-blind, Phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. ASH 2021;Abstract 697.
Perl AE et al. Follow-up of patients with FLT3-mutated R/R AML in the Phase III ADMIRAL trial. ASCO 2021;Abstract 7013.
Pratz KW et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2021;[Online ahead of print]. Abstract
Quizartinib added to chemotherapy demonstrates superior overall survival compared to chemotherapy alone in adult patients with newly diagnosed FLT3-ITD positive AML [press release]. November 18, 2021. https://www.biospace.com/article/releases/quizartinib-added-to-chemotherapy-demonstrates-superior-overall-survival-compared-to-chemotherapy-alone-in-adult-patients-with-newly-diagnosed-flt3-itd-positive-aml/
Short NJ et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: Results from a Phase I/II study. ASH 2021;Abstract 696.
Wang ES et al. Phase 3, open-label, randomized study of gilteritinib and azacitidine vs azacitidine for newly diagnosed FLT3-mutated acute myeloid leukemia in patients ineligible for intensive induction chemotherapy. ASH 2021;Abstract 700.
Wang J et al. Gilteritinib versus salvage chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia: A Phase 3, randomized, multicenter, open-label trial in Asia. ASH 2021;Abstract 695.
Wei AH et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer J 2021;11(10):163. Abstract
Gail J Roboz, MD
Ades L et al. Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): The ideal phase 2 study by the GFM group. ASH 2021;Abstract 63.
Bernard E et al. Molecular International Prognosis Scoring System for myelodysplastic syndromes. ASH 2021;Abstract 61.
Brunner AM et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a Phase Ib study. ASH 2021;Abstract 244.
Fenaux P et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32(2):142-56. Abstract
Garcia JS et al. Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine. ASCO 2021;Abstract 7041.
Garcia JS et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. ASH 2021;Abstract 241.
Garcia-Manero G et al. Luspatercept reduces red blood cell transfusions in patients with lower-risk myelodysplastic syndromes regardless of baseline transfusion burden in the MEDALIST study. EHA 2021;Abstract EP920.
Garcia-Manero G et al. Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndrome (MDS): The Phase 3, randomized, ENHANCE study. ASH 2021;Abstract 3706.
Garcia-Manero G et al. Oral decitabine/cedazuridine in patients with lower risk myelodysplastic syndrome: A longer-term follow-up of from the Ascertain study. ASH 2021;Abstract 66.
Komrokji RS et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromes. ASH 2021;Abstract 536.
Sebert M et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): The Idiome Phase 2 study by the GFM group. ASH 2021;Abstract 62.